Acura Pharma names new CEO
Jones joined Acura in April 2008 as the senior vice president and COO and was reponsible for products development, which use the company’s proprietary abuse deterrent technologies. Acura’s
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.